Trainee Pearls

https://anchor.fm/s/758c8fb4/podcast/rss

4 Followers 16 Episodes Claim Ownership

Welcome to “Trainee Pearls”, a new initiative brought to you by the EBMT Trainee Committee to deliver the most important messages (“the pearls”) of high-profile research works in hematology and bone marrow transplant to our fellow trainees all over the world. The topics will span from classical hematology to more focused bone marrow transplant research. The selected research article will be discussed directly with young authors who have been involved with the published work.

Episode List

#18 Jurjen Versluis: Transplant for high-risk MDS

Oct 29th, 2023 9:00 AM

Allogeneic hematopoietic cell transplantation (HCT) in patients with myelodysplastic syndrome (MDS) improves overall survival. The authors evaluated the impact of MDS genetics on the benefit of HCT in a biological assignment (donor v no donor) study. https://pubmed.ncbi.nlm.nih.gov/37607457/ ALSO AS VIDEO ON https://youtu.be/JbHS_-2sJQc CONNECT WITH US https://twitter.com/TheEBMT_Trainee https://www.ebmt.org/trainee-committee https://twitter.com/CarmeloGurnari

#17 Nathanial Anderson: Signatures and persistence of CAR-T cells

Sep 5th, 2023 12:57 PM

In this study, Nathanial and colleagues systematically analyzed CD19 CAR-T cells of 10 children with R/R B-ALL enrolled in the CARPALL trial via high-throughput single-cell gene expression and T cell receptor sequencing of infusion products and serial blood and bone marrow samples up to 5 years after infusion. Article: https://www.nature.com/articles/s41591-023-02415-3 As VIDEO on https://youtu.be/z_aJgRHpEaI

#16 Aina Oliver-Caldés: Academic CAR-T cells for myeloma

Jul 14th, 2023 11:48 AM

Chimeric antigen receptor (CAR) T-cell therapy is a promising option for patients with heavily treated multiple myeloma. Point-of-care manufacturing can increase the availability of these treatments worldwide. Aina and colleagues assessed the safety and activity of ARI0002h, a BCMA-targeted CAR T-cell therapy developed by academia, in patients with relapsed or refractory multiple myeloma. https://pubmed.ncbi.nlm.nih.gov/37414060/ ALSO AS VIDEO ON https://youtu.be/Ymgg22roWGU CONNECT WITH US https://twitter.com/TheEBMT_Trainee https://www.ebmt.org/trainee-committee https://twitter.com/CarmeloGurnari

#15 Francesca del Bufalo: CAR-T cells for neuroblastoma

May 20th, 2023 7:52 AM

Immunotherapy with chimeric antigen receptor (CAR)–expressing T cells that target the disialoganglioside GD2 expressed on tumor cells may be a therapeutic option for patients with high-risk neuroblastoma. In an academic, phase 1–2 clinical trial, the investigators enrolled patients (1 to 25 years of age) with relapsed or refractory, high-risk neuroblastoma in order to test autologous, third-generation GD2-CAR T cells expressing the inducible caspase 9 suicide gene (GD2-CART01). https://www.nejm.org/doi/full/10.1056/NEJMoa2210859 ALSO AS VIDEO ON YOUTUBE https://youtu.be/o1DVDcrrHFA CONNECT WITH US https://twitter.com/TheEBMT_Trainee https://www.ebmt.org/trainee-committee https://twitter.com/CarmeloGurnari

#12 Justin Loke: Cytogenetics and TP53 in BMT for AML

Dec 5th, 2022 7:18 PM

The presence of TP53 mutations is associated with an unfavorable outcome in patients allografted for acute myeloid leukemia (AML), leading some to question the benefit of an allogeneic stem cell transplantation (allo-SCT) for this patient group, although this has not been studied in a large cohort. Article: https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.34268 ALSO AS AUDIO ON https://podcasts.apple.com/us/podcast/trainee-pearls/id1596786132 https://open.spotify.com/show/2M1PWPZGW9Bz7PL5eh103Y CONNECT WITH US https://twitter.com/TheEBMT_Trainee https://www.ebmt.org/trainee-committee https://twitter.com/CarmeloGurnari

More Episodes